Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rainbowfish: Risdiplam in Presymptomatic Infants With SMA
NCT03779334Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Aug 2019
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of risdiplam in spinal muscular atrophy (SMA), sponsored by Roche. Started Aug 2019; status: active, not recruiting.
02
Drugs
risdiplam
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT03779334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03779334.